Skip to Content
COVIDCOVID
  • Review
  • Open Access

29 June 2023

12 Pages

Harnessing Antiviral Peptides as Means for SARS-CoV-2 Control

,
,
,
,
and
1
Department of Pharmaceutics, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas 79166-13885, Iran
2
School of Dentistry, Marquette University, Milwaukee, WI 53233, USA
3
Department of Molecular Medicine, USF Health Byrd Alzheimer’s Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
4
Autlan Regional Hospital, Health Secretariat, Autlan 48900, Jalisco, Mexico

Abstract

Several times during the past two decades, epidemic viral diseases created global challenges. Although many solutions have been proposed to deal with this tight spot, it is still believed that public vaccination represents the most effective strategy to handle it. So far, various kinds of vaccines including protein subunits, virus-like particles, inactivated, live attenuated, viral vectors, RNA, and DNA vaccines have been used in the prevention of COVID-19. Among the various categories of vaccines, peptide vaccines have created a new hope for quick and trustworthy access due to the development of proteomics equipment. This review specifically focuses on vaccines and peptide therapies in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We consider here the efficacy and safety of subunit and synthetic peptides vaccine in clinical trial phases. Furthermore, monoclonal antibodies with the ability to suppress the development of SARS-CoV-2, those candidates that have entered into clinical trials until March 2023, were selected and evaluated.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.